Accreditation Information

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participantswill earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 7 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.*

By attending this activity and providing your ABIM or ABP number and Date of Birth, you authorize BUSM CME office to report your information to the ACCME so that we may process your MOC Part II credit on your behalf.

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Contact Hours: 9.18 of which 5.59 is eligible for pharmacology credit.

According to the Criteria of the American Board of Certification for Gastroenterology Nurses (ABCGN), the approved hours in this activity are considered GI specific for the purpose of recertification by contact hours through ABCGN.  (7.5 Cat 1 hours)

 

Objectives

At the conclusion of this activity, participants will be able to (or better able to):

  1. Evaluate key considerations and the latest emerging data for managing IBD in the era of COVID-19.
  2. Determine the benefits and risks of biologic treatments in patients with IBD.
  3. Discuss novel agents that are available and those in clinical trials for IBD in terms of therapeutic target, safety, and efficacy.
  4. Discuss the role of therapeutic drug monitoring.
  5. Describe how to treat the pregnant IBD patient.
  6. Discuss issues related to men’s health in IBD.
  7. Evaluate the role of nutrition in the control of IBD, and understand how diet affects microbiota.
  8. Review the role of diagnostic imaging and endoscopic biopsy in the diagnosis and monitoring of Crohn disease and UC.
  9. Identify the most current approaches to the management of postoperative recurrence in CD
  10. Describe the medical and surgical approaches in patients with severe UC and pouchitis.
  11. Recognize the benefits of health maintenance (immunizations, psychosocial screening, and skeletal health assessment) in patients with CD and UC.
  12. Recognize how to effectively advocate for your patient when third party payors or specialty pharmacies deny care or access to needed treatments.
  13. Evaluate and treat extraintestinal manifestations in IBD.

 

Target Audience

This course is designed for practicing gastroenterologists, pediatric gastroenterologists, colorectal surgeons, NP/PAs, nurses and other health care professionals caring for patients with CD and UC.

 

Faculty Disclosure

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.